Pipeline

TARIS is leveraging its unique expertise in bladder biology to develop powerful new treatment options for a range of serious bladder diseases.

PROGRAM

RESEARCH

PHASE 1b

PHASE 2

PHASE 3

Muscle Invasive Bladder Cancer (MIBC)

MIBC: Patients not Receiving Curative Tx

TAR-200

MIBC: Patients not Receiving Curative Tx

TAR-200

MIBC: Collaboration Program (BMS)

TAR-200 + Opdivo®

MIBC: Collaboration Program (BMS)

TAR-200 + Opdivo®

Overactive Bladder (OAB)

OAB

TAR-302

OAB

TAR-302

Additional Programs

Research Programs

Undisclosed

Research Programs

Undisclosed

Bladder Cancer

TAR-200

TARIS is advancing TAR-200 for the treatment of muscle-invasive bladder cancer (MIBC). This system continuously administers the chemotherapeutic agent, gemcitabine, for multiple weeks. TAR-200 has the potential to harness both cytotoxic and immuno-oncologic activity, without meaningful systemic drug exposure. This may yield a powerful new therapy while mitigating the potential for systemic side-effects.

A large portion of MIBC patients do not receive potentially curative therapy (radical cystectomy or curative radiotherapy). These patients have no meaningful therapeutic options, suffer from substantial symptom burden, and often quickly succumb to their disease. TAR-200 has the unique potential to markedly improve survival and overall outcomes for these profoundly underserved patients. TARIS is committed to rapidly advancing TAR-200 for this indication.

TAR-200 + OPDIVO® (NIVOLUMAB)

TARIS is investigating TAR-200 in combination with Opdivo® (nivolumab), as part of a clinical collaboration with Bristol-Myers Squibb. This Phase 1b trial is evaluating the combination in patients with MIBC who are scheduled for radical cystectomy.

Overactive Bladder

TAR-302

TARIS is advancing TAR-302 for the treatment of overactive bladder (OAB). This system continuously administers the antimuscarinic agent trospium for multiple months. TAR-302 has the potential to substantially improve efficacy while minimizing the bothersome systemic side effects usually associated with the treatment of OAB. We believe TAR-302 has the potential to be the best available therapy for patients who are unsatisfied with oral treatments.

In our multi-center Phase 1b study, we evaluated TAR-302 in 11 patients with idiopathic OAB who did not respond to oral therapy and who were experiencing an average of more than five daily urge incontinence episodes.

Following dosing for 42 days, the study demonstrated a…

75%

reduction in mean daily episodes (p=0.0049).

© Copyright 2019 - TARIS BIOMEDICAL LLC | ALL RIGHTS RESERVED.